Spinoff situation: Harvard Apparatus Regenerative Tech

HART is a development-stage company that has successfully grown replacement tracheas (airways) out of a patient’s own stem cells.  These replacement tracheas are then transplanted back into the patient’s body.  This is a huge improvement over the traditional method of transplanting a donor trachea, which requires the patient to be on expensive immune-suppressing drugs that shorten their lifespan and have other complications.

HART has a market cap of $38M ($4.77/share).  At the time of the spinoff, the company had $15M in cash and had spent around $16.5M developing its technologies so far ($31.5M in total).  Given the risks in developing this technology, I believe that this spinoff may be undervalued.

Continue reading

Advertisements

Metanor Resources: Trying to dig itself out of a hole

Metanor Resources trades on the TSX Venture exchange under the symbol MTO.  At 14 cents/share, its market cap is $37.42M.

Excluding its mining assets, the company has around $11.522M of assets versus $52.633M of liabilities.  This would imply a value of $78.531M for the mining assets.  The cash flow of their flagship Bachelor Lake mine suggest that the mining assets aren’t worth anything near $78.5M.  The shareholders may very well be wiped out.

Continue reading